A 38-year-old woman is found to have markedly elevated fasting triglycerides (520 mg/dL) and total cholesterol (380 mg/dL) on routine screening. LDL-C is 90 mg/dL and HDL-C is 28 mg/dL. She reports a family history of premature myocardial infarction in her father (age 48) and maternal uncle (age 52). She is not on any medications. Abdominal examination reveals hepatosplenomegaly. What is the most appropriate next step in management?

Explanation

## Clinical Presentation Analysis This patient presents with: - **Severe hypertriglyceridemia** (520 mg/dL, normal <150 mg/dL) - **Disproportionately elevated total cholesterol** relative to LDL-C - **Low HDL-C** (28 mg/dL) - **Hepatosplenomegaly** (suggesting lipid accumulation) - **Strong family history** of premature coronary artery disease ## Differential Diagnosis Considerations | Feature | Type III Hyperlipoproteinemia | Type IV/V Hyperlipoproteinemia | Familial Chylomicronemia | |---------|-------------------------------|-------------------------------|------------------------| | TG level | 200–500 mg/dL | 200–1500 mg/dL | >1000 mg/dL | | LDL-C | Elevated | Normal/low | Low | | Lipid pattern | Remnants + VLDL | VLDL predominant | Chylomicrons | | Eruptive xanthomas | Yes | Possible | Yes | | Hepatosplenomegaly | Possible | Possible | Yes | | Lipoprotein electrophoresis | Broad β band | Type IV/V pattern | Type I pattern | **Key Point:** The combination of severe hypertriglyceridemia with hepatosplenomegaly and strong family history suggests a **monogenic dyslipidemia** (e.g., Type III, Type V, or familial chylomicronemia). Standard statin monotherapy is insufficient; phenotyping via lipoprotein electrophoresis is essential before treatment escalation. ## Why Lipoprotein Electrophoresis Is the Next Step 1. **Identifies the lipid phenotype** — determines whether chylomicrons, VLDL, or remnants predominate 2. **Guides therapy selection** — Type I requires dietary fat restriction; Type III responds to fibrates + statins; Type V requires fibrates ± niacin 3. **Assesses risk of acute pancreatitis** — TG >500 mg/dL with chylomicronemia warrants urgent triglyceride reduction 4. **Evaluates secondary causes** — rules out secondary hypertriglyceridemia (uncontrolled diabetes, hypothyroidism, renal disease) **High-Yield:** Apolipoprotein B and lipoprotein(a) measurements help refine genetic diagnosis and assess residual cardiovascular risk after triglyceride normalization. ## Management Algorithm ```mermaid flowchart TD A[Severe Hypertriglyceridemia + Family Hx]:::outcome --> B[Lipoprotein Electrophoresis]:::action B --> C{Phenotype?}:::decision C -->|Type I| D[Dietary fat restriction]:::action C -->|Type III| E[Fibrate + Statin]:::action C -->|Type IV/V| F[Fibrate ± Niacin]:::action D --> G[Monitor TG, assess pancreatitis risk]:::action E --> H[Recheck lipids in 4 weeks]:::action F --> I[Recheck lipids in 4 weeks]:::action ``` **Clinical Pearl:** Patients with TG >500 mg/dL are at high risk for acute pancreatitis. Hepatosplenomegaly suggests lipid deposition in organs, indicating a severe phenotype requiring urgent phenotyping and targeted therapy. [cite:Harrison 21e Ch 402, Robbins 10e Ch 7]